MedTrace Logo

Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma

NCT05236439 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and primary narrow angle glaucoma (PNAG) who have failed at least one class of topical medical therapy

Conditions

  • Glaucoma, Open-Angle
  • Glaucoma, Narrow Angle

Interventions

DEVICE

Interposition supraciliary implant

Surgical placement of SV22 interposition supraciliary implant in the supraciliary space

Sponsors & Collaborators

  • Clinchoice Inc

    collaborator UNKNOWN

  • Ciliatech

    lead INDUSTRY

Principal Investigators

  • Lilit Voskanyan · Malayan Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2025-02-19
Completion
2025-11-03

Countries

  • Armenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05236439 on ClinicalTrials.gov